PYC Therapeutics (PYC) Q3 2024 TU earnings summary

Executive summary

• Advancing three first-in-class, disease-modifying RNA drugs into human studies, with polycystic kidney disease program entering clinical development soon.

• Focused on rare, monogenic diseases with high unmet need, leveraging RNA therapeutics and proprietary delivery technology.

• Pipeline includes RP11 (retinitis pigmentosa type 11), polycystic kidney disease, autosomal dominant optic atrophy, and Phelan-McDermid syndrome.

• All major programs are on track for significant 2024 milestones, including human safety and efficacy data for RP11 and optic atrophy, and regulatory submission for polycystic kidney disease.

• Multiple clinical readouts expected in the next 12–18 months, marking a critical inflection point.

Outlook and guidance

• Anticipates pivotal study in lead indication within 12 months, pending proof of concept and favorable risk-benefit profile.

• Expects initial safety data from polycystic kidney disease program and efficacy signals in autosomal dominant optic atrophy.

• Phelan-McDermid syndrome program to nominate a clinical candidate and enter translational studies by year-end.

• Registrational study for RP11 planned for next year, with design informed by upcoming multiple dose data and regulatory input.

• Company anticipates transition to commercial stage for RP11 by 2028, pending successful clinical and regulatory outcomes.

Segment performance

• RP11: Completed single ascending dose study with no safety issues; multiple dose studies underway, with early efficacy signals showing prevention of progression and some reversal of vision loss.

• Autosomal dominant optic atrophy: Received rare pediatric disease designation from FDA; human safety data imminent.

• Polycystic kidney disease: Finalizing preclinical package for first-in-human studies.

• Pipeline targets distinct monogenic diseases, including retinitis pigmentosa type 11, polycystic kidney disease, autosomal dominant optic atrophy, and Phelan-McDermid syndrome.